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a  b  s  t  r  a  c  t
The  effectiveness  of vaccinating  males  against  the human  papillomavirus  (HPV)  remains  a controversial
subject.  Many  existing  studies  conclude  that  increasing  female  coverage  is  more  effective  than  diverting
resources  into  male  vaccination.  Recently,  several  empirical  studies  on HPV  immunization  have  been
published,  providing  evidence  of  the fact that  marginal  vaccination  costs  increase  with  coverage.  In this
study,  we use a  stochastic  agent-based  modeling  framework  to  revisit  the  male  vaccination  debate  in  light
of these  new  ﬁndings.  Within  this  framework,  we  assess  the  impact  of  coverage-dependent  marginal  costs
of vaccine  distribution  on  optimal  immunization  strategies  against  HPV.  Focusing  on  the  two  scenarios
of  ongoing  and  new  vaccination  programs,  we analyze  different  resource  allocation  policies  and  theirtochastic agent-based models
ale HPV vaccination
ptimal vaccine distribution
effects  on  overall  disease  burden.  Our  results  suggest  that  if  the  costs  associated  with  vaccinating  males
are relatively  close  to those  associated  with  vaccinating  females,  then  coverage-dependent,  increasing
marginal  costs  may  favor  vaccination  strategies  that  entail  immunization  of  both  genders.  In particular,
this  study  emphasizes  the  necessity  for further  empirical  research  on the  nature  of  coverage-dependent
vaccination  costs.
©  2015  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).ntroduction
The sexually transmitted human papillomavirus (HPV) is a sig-
iﬁcant global public health burden. Almost all cervical cancers,
p to 90% of anal cancers, and up to 60% of oropharyngeal cancers
re caused by HPV (Crow, 2012). In the USA alone, the incidence of
ew HPV-related cancer cases in 2009 exceeded 35,000, with more
han a third of cases occurring in the male population (Jemal et al.,
013). Although screening has led to a signiﬁcant decrease in cer-
ical cancer incidence and mortality in developed countries, there
as been an increase in other HPV-related cancers for which pop-
lation screening is not currently performed (Simard et al., 2012;
hiels et al., 2012). The introduction of effective prophylactic vac-
ines against HPV-16 and HPV-18, the two types responsible for
0% of cervical cancers, as well as most anal and oropharyngeal
PV-related cancers, provides an additional strategy for preventing
∗ Corresponding author at: Duke University, Box 90320, Durham, NC 27708, USA.
el.: +1 919 660 2847; fax: +1 919 660 2821.
E-mail address: ryser@math.duke.edu (M.D. Ryser).
ttp://dx.doi.org/10.1016/j.epidem.2015.01.003
755-4365/© 2015 The Authors. Published by Elsevier B.V. This is an open access article unmorbidity and mortality. Although both commercially available
HPV vaccines were originally approved for use in girls and women
only, the quadrivalent vaccine (Gardasil © Merck, Inc., Whitehall
Station, NJ) was approved by the US Food and Drug Administration
in 2009 for use in boys and men. Despite vaccination of boys being
recommended by the Centers for Disease Control and Prevention
(2014), vaccine coverage in adolescent males remains low in the
United States, where it is currently around 13.9% (Stokley et al.,
2014).
Whether allocating further resources to increase low coverage in
adolescent males is more effective than vaccinating females alone
remains controversial. Existing studies vary in their conclusions,
with most ﬁnding that targeting females alone is most cost effec-
tive: see Elbasha and Dasbach (2010) (see also Elbasha et al., 2007),
Taira et al. (2004), Kim et al. (2007), Kim and Goldie (2009), Brisson
et al. (2011), Bogaards et al. (2011), Chesson et al. (2011), and Seto
et al. (2012) for a review. A common assumption in all of these stud-
ies is that the vaccination costs consist of direct costs (i.e., vaccine
price) only. However, several recent publications indicate that an
increase in coverage might be subject to additional marginal costs
of vaccine distribution. In fact, the number of preadolescent and
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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arly adolescent girls in the USA who have completed the full vac-
ine series appears to have plateaued around 37% (Stokley et al.,
014), which is a much lower coverage level than was  assumed by
revious analyses (e.g., 75% in Kim and Goldie, 2009). In addition,
he willingness of parents to have their preadolescents vaccinated
ay  be decreasing, with 44% of US parents opposing vaccination
Darden et al., 2013). Together, these ﬁndings suggest that a fur-
her increase in female coverage will require costly education and
utreach programs to reach the unvaccinated population, result-
ng in increasing marginal costs in addition to direct vaccine costs.
he necessity to study the potential impact of these additional
osts on optimal resource allocation has been emphasized previ-
usly (Elbasha and Dasbach, 2010; Bogaards et al., 2011), but to
ur knowledge the issue has not yet been addressed explicitly.
In this study, we develop an agent-based modeling framework
o assess the impact of coverage-dependent marginal vaccination
osts on optimal resource allocation policies for vaccination against
PV. We  do so by considering two different scenarios. First, we
ssess globally optimal resource allocation in the case of new vac-
ine programs. In this scenario, which is particularly relevant to
ountries without an HPV vaccination program, we  seek to iden-
ify allocation policies that yield a maximum decrease in disease
urden. In the second scenario, we optimize the distribution of
esources in the case where a positive fraction of the population
s already vaccinated.
odel description and validation
Various groups have developed mathematical models to opti-
ize vaccination strategies against HPV (Elbasha and Dasbach,
010; Elbasha et al., 2007; Taira et al., 2004; Kim et al., 2007;
im and Goldie, 2009; Brisson et al., 2011; Bogaards et al., 2011;
hesson et al., 2011; Seto et al., 2012). Among these models, there
re stochastic agent-based models (e.g., Brisson et al., 2011), deter-
inistic compartment models (e.g., Bogaards et al., 2011), and
ybrid models (e.g., Kim and Goldie, 2009). Over the past years,
t has been emphasized that the heterogeneity of sexual networks
lays an important role in disease transmission (see Durrett (2010)
or a detailed discussion). In particular, time-ordering (Moody,
002; Carvalho and Goncalves, 2012), assortativity (Malagón et al.,
013), and concurrency (Goodreau, 2011) of relationships in sexual
etworks are now recognized as important mechanisms affecting
he spread of sexually transmitted infections. Acknowledging the
mportance of these mechanisms, we develop a stochastic agent-
ased model (ABM), in which stochastic infection dynamics of
IR/S-type take place on a dynamic random graph model of sexual
etwork evolution. In addition, we develop a compartment model
CM) that provides an analytically tractable simpliﬁcation of the
BM and yields qualitatively similar results despite its simplicity.
odel development
We  consider a cohort of sexually active adolescents, contain-
ng N females and N males. Individuals enter the cohort at age 14
nd leave when they turn 19 years old. Depending on the mag-
itude of N, the model can describe, for example, the network of
tudents in a single high school, or the entire adolescent population
n a given town or geographic region. For simplicity, we  consider
nly heterosexual relationships; the role of bi- and homosexual
elationships is addressed in “Discussion” section. As illustrated in
ig. 1A, each of the N2 possible male-female pairs (edges) in the
ohort initiates a relationship at rate e1 and can engage in sexual
ctivity until dissolution of the relationship, which occurs at rate
0. The rates e1 and e0 vary by edge, enforcing assortative mixing
ccording to age and sexual activity level. Regarding the latter, wecs 11 (2015) 32–47 33
follow Van de Velde et al. (2010) and categorize individuals into
four groups, L0, . . .,  L3, ranging from low (L0) to high (L3) sex-
ual activity. In keeping with studies of teenage sexual networks,
we allow for concurrency, i.e. individuals are permitted to have
more than one relationship simultaneously (Bearman et al., 2004;
Doherty et al., 2007; Rosenberg et al., 1999).
We  model the dynamics of genital infections with HPV-16 and
HPV-18 only. In fact, HPV-16/18 are the main oncogenic strains and
account for roughly 70% of HPV-associated cancers (Crow, 2012).
Moreover, they are the only oncogenic strains covered by vaccines
currently available to the public. There is currently no compelling
evidence for either synergy or competition between vaccine types
and non-vaccine types (Chaturvedi et al., 2011; Goldman et al.,
2013). Consequently, we assume that transmission, acquisition and
clearance of HPV-16/18 are independent of co-infection with other
strains. As illustrated in Fig. 1B, susceptible individuals can become
infected when engaging in sexual activity with infected individuals.
We  denote the per-relationship transmission rate from infected
females (males) to susceptible males (females) by ˇfm (ˇmf). The
total numbers of susceptible and infected females are denoted by
Sf and If, respectively, with analogous notation for males. Most HPV
infections are transient (Evander et al., 1995), and we assume that
infected individuals clear the virus at rates f and m, respectively.
The number of recovered females (males) is denoted by Rf (Rm).
Since we are interested in different vaccination strategies, we  intro-
duce vf (vm), the fraction of vaccinated females (males). For the
purpose of this study, we only consider completed vaccinations
(3 doses), and we assume a vaccine efﬁcacy of 100%. A detailed
description of the ABM is found in “Agent-based model” section in
Appendix A.
Large population limit
In addition to the ABM, we  introduce a deterministic CM.  Due  to
its simplicity, the CM is analytically tractable, and enables more sys-
tematic analyses such as the roadmap to herd immunity in “Local
analysis: roadmap to herd immunity” section. To derive the CM,
we neglect network heterogeneity and assortativity in the ABM
approach and pass to the large population limit (N →∞). The result-
ing deterministic transmission model is described by the following
set of ordinary differential equations (see “Deterministic compart-
ment model” section in Appendix B for details):
S˙m = (1 − vm) − ˇfmSmIf − Sm,
I˙m = ˇfmSmIf − ( + )Im,
R˙m = mIm − Rm,
(1)
where the equations for the female variables are analogous, with
the subscripts interchanged. The notation is the same as for the
ABM, expect that ˇfm and ˇmf are now effective transmission rates,
corresponding to the per-relationship transmission rates from the
ABM model multiplied by a scaling factor related to effective net-
work connectivity. Note that we  have normalized the variables by
the total population size, so they represent relative fractions rather
than absolute numbers. A brief discussion of basic properties of sys-
tem (1) and its basic reproductive number R∗ is found in “Model
description” section in Appendix B.
Model parametrization
The parametrization of the network part of the ABM was  par-
tially based on estimates provided in the work of Van de Velde
et al. (2010). To enable a direct parameter comparison between
our and Van de Velde’s model, we  had to rescale our edge forma-
tion rate e1 by a dimensionless scaling factor E. In a ﬁrst step, we
34 M.D. Ryser et al. / Epidemics 11 (2015) 32–47
Fig. 1. Stochastic model dynamics. (A) The N male (black) and N female (gray) nodes initiate and dissolve relationships at rates e1 and e0, respectively. The edge rates depend
on  the age and sexual activity levels of the associated individuals. (B) The disease dynamics on the random graph are of SIR/S-type with immigration and death. Susceptible
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pndividuals (Sm/f) enter the network at age 14, with a probability vm/f of being vaccina
nd  the infection rate m/f of a given node depends on the current number of infected
nter  the compartments of recovered nodes (Rm/f) with probability pm/f or re-ente
eterministically and leave the system upon turning 19 years old, so that the total n
arametrized the network part of the ABM. To account for param-
ter uncertainty (i.e. large prior ranges) we applied a dynamic
e-sampling scheme for most network parameters (see “Network
arametrization” section in Appendix A for details). More precisely,
uring simulations we re-sampled these parameters uniformly
cross their prior ranges every t  = 0.025 years (≈10 days). The
caling factor E on the other hand was inferred by ﬁtting the degree
istribution of the simulated sexual network to the degree dis-
ribution of a high school sexual network described in (Bearman
t al., 2004), see “Network calibration” section in Appendix A for
etails. Once the network part of the model was parameterized,
e used longitudinal data on prevalence of HPV-16/18 in adoles-
ents (Markowitz et al., 2013) together with vaccine uptake data
Centers for Disease Control and Prevention, 2014) to infer the
iral transmission and clearance rates. We  tested 1000 prior sets
or the disease parameters, from which only 26 sets satisﬁed our
riteria of a good ﬁt. We  call these the Posterior Sets, and all ABM
esults throughout this study are presented in terms of these Pos-
erior Sets, which are listed in Table 8. A detailed description of the
BM parametrization is found in “Simulations” to “Disease dynam-
cs parametrization” sections in Appendix A, and a summary of the
BM parameters and their prior ranges is given in Table 1.
To parametrize the CM,  we used the 26 Posterior Sets
rom the ABM, and rescaled the viral transmission rates by a
able 1
odel parameters: summary. Prior ranges are for dynamically sampled and inferred 
arameters, Group 3: parameters sampled for each individual separately. Units for rates:
Parameter Name Prior range Value Group 
(a, a′) Age mixing matrix – Table 2 1 
E e1 scaling – 1.5 1 
(g, a, l) Initiation rate Table 3 – 2 
ˆ(a, l) Dissolution rate Table 4 – 2 
 Assortative degree [65, 140] – 2 
	(l) Activity level fractions Table 5 – 3 
ˇmf m–f  transmission [1.6, 187] Posterior Set 1 
ˇfm f–m transmission [1.6, 187] Posterior Set 1 
 Clearance rate [0.63, 1.88] Posterior Set 1 
pm Prob. of immunity [0.1, 0.85] – 3 
pf Prob. of immunity [0.2, 0.9] – 3 m/f). Disease transmission takes place between infected (Im/f) and susceptible nodes,
ers. Infected individuals clear the virus at rate . Upon clearing the virus, individuals
ompartments of susceptible nodes (Sm/f) with probability 1 − pm/f . Individuals age
r of individuals in the system is conserved.
network connectivity parameter to account for the differences
in network structure between the ABM and the CM.  For each
Posterior Set, the connectivity parameter was estimated sepa-
rately by ﬁtting the CM-derived prevalence levels to the empirical
data as described above for the ABM. CM results throughout this
study are presented in terms of the 26 Posterior Sets (includ-
ing the network connectivity parameter). Details on the CM
parametrization are found “Model parametrization” section in
Appendix B.
The costs and beneﬁts of vaccination
Conclusions drawn from mathematical vaccination models nat-
urally depend on the underlying choices of cost and beneﬁt
measures. Several authors have called for a more detailed analysis
of the relationship between these measures and optimal vacci-
nation strategies against HPV (Bogaards et al., 2011; Elbasha and
Dasbach, 2010). Here, we  follow their call and assess how coverage-
dependent costs impact optimal vaccination strategies. Since the
nature of these cost functions is largely unknown, we work with
a general class of functions, subject to a few natural assumptions.
More precisely, we assume that the cost of vaccinating a proportion
vm of males and vf of females is a non-negative function C(vm, vf )
satisfying the following two  conditions:
parameters only; Group 1: ﬁxed parameters, Group 2: dynamically re-sampled
 per year.
Type Refs.
Fixed Kaestle et al. (2002)
Inferred Bearman et al. (2004)
Sampled Van de Velde et al. (2010)
Sampled Van de Velde et al. (2010)
Sampled Van de Velde et al. (2010)
Sampled Van de Velde et al. (2010)
Inferred Hernandez et al. (2008), Widdice et al. (2013), Burchell et al. (2011)
Inferred Hernandez et al. (2008), Widdice et al. (2013), Burchell et al. (2011)
Inferred Giuliano et al. (2011), Moscicki et al. (2004)
Sampled Van de Velde et al. (2010)
Sampled Van de Velde et al. (2010)
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Fig. 2. Beneﬁt under symmetric cost curves. (a) The three curves A–C are ﬁxed-cost
curves with differing levels of convexity (for the corresponding ratios of marginal
administration to marginal ﬁxed costs, see Fig. 8): linear curve with no marginal
costs associated with vaccine administration (A), mildly convex curve with high
marginal costs of vaccine administration (B), and more convex curve with low
marginal costs of vaccine administration (C). Maximal single-sex coverage is 35%
for  all three curves. In the region below the dotted line there is an endemic equi-
librium (R∗ > 1). Vaccination coverage on and above the dotted line confers herd
immunity (R∗ ≤ 1). (b) Moving along the level-sets of the cost functions A–C in (a),
the  vaccination beneﬁt B(vm, vf ) is shown as a function of vm for  = 0. (c) Same as
(b)  but with  = 1/2. In (a) and (b), 25 simulations for each of the 26 Posterior Sets
were run for 30 years. Prevalence levels were time-averaged between 15 and 30
years for each run, and the time averages were in turn averaged over the 25 real-M.D. Ryser et al. / Ep
1) C(vm, vf ) > 0 for all vm + vf > 0,
2) ∂C
∂vm
≥ cm > 0, ∂C∂vf ≥ cf > 0.
Condition (1) says that it always costs something to vaccinate
n individual, while (2) accounts for a minimal per-person cost,
m/f > 0, of administering the vaccine. Importantly, these conditions
o not specify the local curvature of the cost function, allowing for
ifferent scenarios. For example, one would expect to spend less
oney to raise coverage from 10% to 11% than to raise it from 40%
o 41%, since a certain proportion of the population may  be difﬁ-
ult to vaccinate (Darden et al., 2013). However, the corresponding
ncreasing marginal costs may  not apply at all coverage levels. In
act, economies of scale and network externalities could play a role
t higher coverage levels, leading to locally concave cost functions
Bishai et al., 2006). Examples of cost-function level curves in a
xed-resource setting where C(vm, vf ) = K for some K > 0, are found
n Fig. 2a.
To quantify the beneﬁts of vaccination, we introduce the beneﬁt
unction B(vm, vf ),
(vm, vf ) ≡ 1 − Itot(vm, vf ), [0,  1],  (2)
here Itot(vm, vf ) is the burden of infection, deﬁned as

tot(vm, vf ) ≡ Im(vm, vf ) + (1 − )If (vm, vf ), [0,  1].  (3)
The latter is a weighted sum of the fraction of infected males and
he fraction of infected females, and  determines the sex-speciﬁc
urden of infection. It ranges from  = 0 (focus on female infections
nly) to  = 1 (focus on male infections only). In fact, the potential
osts associated with a male infection are different from the costs
ssociated with a female infection: the probability to develop an
PV-associated disease is both sex- and site-speciﬁc. Considering
hat in the US and Europe roughly one in three HPV-related cancers
ffect men  (Stanley, 2012; Jemal et al., 2013), it seems reasonable
o assume that  ∈ (0, 1/2). Since the true value of  is difﬁcult to
scertain, we present the model results below for both the lower
 = 0) and upper ( = 1/2) bounds of this interval. As explained in
Estimation of ” section in Appendix C, we estimate the true value
f  to be of the order of  ≈ 7 ·10−3, and model results obtained for
his value are virtually identical to the lower bound  = 0.
Finally, it is important to emphasize that a complete cost-
ffectiveness analysis is not feasible within our framework as
uch an analysis would require extending the cohort to all ages,
nd introducing additional models for cancer progression. Never-
heless, sufﬁcient prevalence levels in adolescent populations are
ritical for the survival of HPV in the entire population. In this sense,
he upper bound  = 1/2, for which I1/2tot (vm, vf ) measures the cohort
revalence of infection, provides valuable information in itself.
esults
A key public health challenge with respect to HPV vaccination is
he optimal allocation of available resources among the population.
ince both males and females can develop symptomatic diseases
hat require medical intervention (e.g. genital warts and various
ancer types), both sexes beneﬁt from immunization. However, the
ptimal distribution of vaccines among males and females is difﬁ-
ult to establish. The most challenging part is the parametrization
f the coverage-dependent costs of vaccination. To our knowledge
here is currently no empirical data on these costs in the speciﬁc
ase of HPV. Despite several authors asking for more detailed anal-
ses regarding the impact of marginal costs (Elbasha and Dasbach,
010; Bogaards et al., 2011), to our knowledge, no previous study
as addressed this issue. The goal of our analysis is to assess their
otential impact on optimal vaccine distribution in different sce-
arios: (i) in countries with no HPV vaccine programs in place,izations per Posterior Set. For each value of vm , the mean, minimum and maximum
beneﬁts across the Posterior Set are represented by the symbol and the error bars,
respectively.
the central issue is how to allocate resources to set up the most
efﬁcient new vaccine program; (ii) in countries with ongoing vac-
cine programs, the main issue is how to invest newly allocated
resources such that herd immunity-conferring coverage levels are
approached most efﬁciently. In “Global analysis: when a mixed
3 idemics 11 (2015) 32–47
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Fig. 3. Compartment model: beneﬁt under symmetric cost curves. (a) Moving along
the cost curves A–C in Fig. 2a, the vaccination beneﬁt B(vm, vf ) is shown as a function
of  vm for  = 0. (b) Same as (a) but with  = 1/2. In (a) and (b), the CM steady states6 M.D. Ryser et al. / Ep
rotocol is optimal” section we address scenario (i) under the
ssumption of symmetric cost curves and homogeneous vaccine
ptake. Next, we study the impact of asymmetric cost curves in
Impact of asymmetric cost curves” section, and assortative vac-
ine uptake in “Impact of assortativity in vaccine uptake” section.
inally, scenario (ii) is addressed in “Local analysis: roadmap to herd
mmunity” section.
lobal analysis: when a mixed protocol is optimal
In this section, we characterize the globally optimal resource
istribution between both sexes. Thereby, the aim is to determine
he optimal strategy along ﬁxed cost curves, C(vm, vf ) = K , where
 > 0 is the amount of allocated resources. This scenario is particu-
arly relevant for low-resource countries with a current lack of HPV
accine programs.
Based on ABM simulations, we determine the vaccine beneﬁt
long three symmetric cost function level sets, see curves A, B, and
 in Fig. 2a, and present the results for  = 0 in Fig. 2b, and for  = 1/2
n Fig. 2c. We  point out two  interesting observations. First, incorpo-
ating coverage-dependent marginal costs drastically changes the
hape of the beneﬁt curve. For the linear cost curve A, the optimal
trategy entails female-only vaccination (vm = 0), and the beneﬁt
ecreases as resources are shifted toward males (vm > 0). In con-
rast, for increasing convexity in the cost curve (curves B and C), the
eneﬁt increases as vm becomes positive. In particular, the maxi-
um  beneﬁt is achieved for a mixed vaccination strategy where
oth genders are vaccinated, and the height of the peak corre-
ates with the convexity of the cost curve. Second, the impact of
overage-dependent costs is, qualitatively speaking, independent
f the  value: the optimal strategy is mixed, whether we  focus
n female prevalence ( = 0) or population prevalence ( = 1/2).
he only qualitative difference between the two cases is found at
he end points (vm = 0 and vm = 0.35) of the beneﬁt curve: while
emale-only vaccination is more beneﬁcial in the case  = 0, the two
ure strategies perform almost identically in the case  = 1/2.
To ascertain whether the above observations were due to par-
icular features of assortativity and heterogeneity in the ABM, we
epeated the analysis using the homogeneously mixing CM from
Large population limit” section. Interestingly, as shown in Fig. 3,
he beneﬁt curves are qualitatively very similar, underscoring the
obustness of the above observations with respect to coverage-
ependent marginal costs.
Finally, we considered potential limitations due to our assump-
ion of a closed sexual network of 14–18 year old adolescents. In
act, there is data suggesting that up 35–40% of females in this
ge group have sexual relationships with males who are at least
 years older (Darroch et al., 1999), raising questions about our
hoice of network closure. To assess the potential impact of such
elationships on our results, we repeated the simulations from
ig. 2 in the presence of additional relationships between females
n the network and older males outside the network. In these
imulations, external males were assigned a probability of being
nfected with HPV-16/18, and they could transfer the disease to
heir female partners inside the network, see “The role of exter-
al relationships” section in Appendix E for details. The simulation
esults (Fig. 9) show that adding external males causes changes
n the overall prevalence levels. Since 20–29 years old males have
igher prevalence levels of HPV-16/18 than younger males inside
he network, see “The role of external relationships” section in
ppendix E for estimates, the external relationships increase the
isease burden among females considerably. This is reﬂected by
he fact that the average beneﬁt for  = 0 (female-only beneﬁt),
ig. 9a and c, is smaller than for  = 1/2 (population beneﬁt),
ig. 9b and d, respectively. However, despite the impact on female
revalence, a comparison between Figs. 9 and Fig. 2 (no externalfor  the 26 Posterior Sets were computed. For each value of vm , the mean, minimum
and  maximum beneﬁts across the Posterior Set are represented by the symbol and
the error bars, respectively.
relationships) shows that adding external relationships does
not change the qualitative nature of the beneﬁt curves. Most
importantly, mixed vaccination strategies remain optimal for the
nonlinear cost curves B and C.
Impact of asymmetric cost curves
The analysis in “Global analysis: when a mixed protocol is opti-
mal” section was based on the gender symmetric cost curves in
Fig. 2a. In other words, we assumed identical marginal costs of
vaccination for males and females. Despite proved efﬁcacy against
infection with HPV-16/18 and the development of lesions in males
(Giuliano et al., 2011; Palefsky et al., 2011), vaccine uptake in
male adolescents (13.9%) is considerably lower than in female ado-
lescents (37%) (Stokley et al., 2014). One possible reason for the
differential uptake may  be a general lack of awareness and knowl-
edge about the role of HPV in cancers other than cervical cancer
(Blödt et al., 2011). Together, the preference to vaccinate females
over males (Liddon et al., 2010), and the low vaccine uptake in
male adolescents, suggest that the marginal costs associated with
male vaccination may  be higher than the marginal costs associated
with female vaccination. To assess the potential impact of this gen-
der speciﬁc asymmetry on the optimal allocation of resources, we
repeated the analysis from “Global analysis: when a mixed protocol
is optimal” section with asymmetric cost curves.
First, starting from the mildly convex (but symmetric) cost curve
B (see Fig. 2a), we added a 25% and 50% increase in male over female
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arginal costs, leading to the asymmetric cost curves B1 and B2,
espectively, see inset of Fig. 4a. As illustrated in Fig. 4a for  = 0 and
ig. 4b for  = 1/2, the asymmetry in the cost curves counterbalances
he effect of the increasing marginal costs: in comparison to the
ymmetric B curve, the global maximum of the beneﬁt function is
hifted toward vm = 0 for curves B1 and B2.
As shown in Fig. 4c and d, the impact of cost asymmetry on the
eneﬁt is smaller when starting from the more convex cost curve C
rom Fig. 2a. Here, increasing the marginal costs for male vaccina-
ion by 25% (C1) and 50% (C2), respectively, still shifts the maximum
eneﬁt toward vm = 0, but the optimal strategy clearly remains of
ixed type, consisting of positive male and female coverages.
mpact of assortativity in vaccine uptake
In the US, the recommended age of HPV vaccination in preteens
s 11–12 years (Centers for Disease Control and Prevention, 2014).
ince this is generally before onset of sexual activity, future sexual
ctivity levels are not known at the time of vaccination. For this
eason, most modeling studies assume uniform distribution of the
accine across the population. However, many socioeconomic and
ociodemographic factors that are associated with sexual behav-
or are also associated with vaccine uptake, and hence it is likely
hat vaccine uptake is associated with future sexual activity lev-
ls; see Malagón et al. (2013) and references therein for a detailed
iscussion of this issue. In this section, we address how differen-
ial vaccine uptake across sexual activity levels may  affect the role
f increasing marginal costs on resource allocation. For this pur-
ose we repeat the analysis from “Global analysis: when a mixed
rotocol is optimal” section, and analyze two different scenarios
f uptake, where vaccine uptake levels are either negatively or
ositively correlated with sexual activity.
To study the case of a negative correlation of vaccine uptake
ith sexual activity, allocated vaccines are distributed across the
opulation such that an individual in the lowest activity level (L0)
s twice as likely to receive a given vaccine than an individual in
he lower intermediate level (L1), 4 times as likely than an indi-
idual in the upper intermediate level (L2), and 8 times as likely
han an individual in the highest activity level (L3). For each allo-
ated vaccine we then draw an individual at random with the
bove relative weights, and either set the individuals’ status to
accinated, or repeat the draw in case the individual had already
eceived a vaccine. This process is iterated until all allocated vac-
ines are distributed. As shown in Fig. 5a for  = 0 and Fig. 5b for
 = 1/2, the beneﬁt curves for this distribution scheme are qualita-
ively similar to the ones obtained under a uniform distribution of
accines, see Fig. 2b and c for comparison. However, the average
eneﬁt is about two percentage points lower when vaccine uptake
orrelates with lower sexual activity (Fig. 5a and b). This high-
ights the dominant role of high activity individuals in the spread
f HPV.
Regarding the case of a positive correlation between sexual
ctivity and vaccine uptake, the vaccines are distributed the other
ay around: an individual in the highest activity level (L3) is twice
s likely to receive a vaccine than an individual in the upper inter-
ediate activity level (L2), 4 times as likely than an individual in
he lower intermediate level (L1), and 8 times as likely than an
ndividual in the lowest activity level (L0). As seen in Fig. 5c for
 = 0 and Fig. 5d for  = 1/2, this vaccine distribution scenario con-
iderably changes the beneﬁt curves in comparison to the case of
niform distribution across the population, see Fig. 2b ( = 0) and
ig. 2c ( = 1/2), respectively. For the linear cost curve A, the beneﬁt
f vaccination remains highest for single-sex vaccination strategies
vm = 0 and vm = 0.35), but for the convex cost curves B and C, the
eneﬁt becomes nearly constant and is close to 1, which means that
he disease burden has nearly vanished.cs 11 (2015) 32–47 37
Local analysis: roadmap to herd immunity
In the previous three sections, we focused on the scenario of
new vaccination policies: assuming an initial coverage level of
zero (vm = vf = 0), we  determined how to best distribute budgeted
resources such that the overall disease burden was minimized. In
the current section, we focus on an alternative scenario with initial
nonzero coverage levels, (vm, vf ) /= (0,  0), and we  are interested in
how to distribute newly allocated resources. In other words, given
the current coverage, we seek to determine whether the next dollar
should be invested in male or female vaccination to decrease the
disease-related burden. This question, raised previously by Elbasha
and Dasbach (2010), is complicated by the fact that marginal costs
and beneﬁts, and hence the optimal strategy, depend on the current
coverage levels.
We  present the results of our analysis in the form of a ‘roadmap
to herd immunity’ as shown in Fig. 6. More precisely, for each level
of coverage corresponding to a point in the (vm, vf )-plane, we  cal-
culate the locally optimal strategy as follows. First, we compute the
marginal beneﬁt to marginal cost ratio of vaccinating males, rm =
∂B
∂vm
/ ∂C
∂vm
, and the corresponding quantity for females, rf = ∂B∂vf /
∂C
∂vf
.
If rm > rf at the given coverage level, then it is marginally more effec-
tive to allocate new resources toward the vaccination of males.
Conversely, if rm < rf at the current coverage level, then vaccinating
more females is marginally more effective. To quantify the uncer-
tainty introduced by the 26 different parameter combinations in
the Posterior Set, we proceeded as follows. For each coverage level
(vm, vf ), we only retained the parameter sets that were endemic
(R∗ > 1), and eliminated all others. Next, we determined the opti-
mal  strategy for the endemic parameter combinations, added their
individual ‘votes’ and normalized so that the uncertainty is visu-
ally represented in color between black (spend new resources on
females) and white (spend new resources on males). As illustrated
in Fig. 6, the magnitude of  (rows) and the convexity of the cost-
curve (columns) have a signiﬁcant impact on the locally optimal
strategy.
Discussion
In most countries with HPV vaccine programs, male vaccine
coverage is low in comparison with female coverage. Whether allo-
cation of resources to increase male vaccination is more effective
than continuing to vaccinate females alone remains a subject of
debate among experts. Several groups have addressed this issue
using mathematical modeling (Elbasha and Dasbach, 2010; Elbasha
et al., 2007; Taira et al., 2004; Kim et al., 2007; Kim and Goldie,
2009; Brisson et al., 2011; Bogaards et al., 2011; Chesson et al.,
2011; Seto et al., 2012), but there is currently no consensus on
an optimal vaccination strategy. However, recent empirical ﬁnd-
ings may  shed new light onto the ongoing debate about optimal
resource allocation. In fact, the coverage level of HPV vaccina-
tion among US females has stagnated over the past three years,
and there is increasing opposition among parents toward get-
ting their daughters vaccinated (Centers for Disease Control and
Prevention, 2014; Darden et al., 2013). These circumstances are
likely to result in signiﬁcant coverage-dependent marginal costs
of vaccine administration, because a further increase in coverage
will require costly education and outreach programs to reach the
unvaccinated population. In light of these ﬁndings, we developed
an agent-based model of adolescent sexual networks to examine
the impact of coverage-dependent marginal costs on optimal vac-
cination strategies against HPV. Our model framework accounts
for several aspects of real-world sexual networks, such as time-
ordered and concurrent relationships, as well as assortativity by age
and sexual activity levels. 26 Posterior Sets (Table 8) for the main
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Fig. 4. Beneﬁt under asymmetric cost curves. (a) and (b) Cost curve B from Fig. 2a is rendered asymmetric (curves B1 and B2 in insets). Moving along these asymmetric cost
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durves,  the beneﬁt B(vm, vf ) is shown for  = 0 in (a) and for  = 1/2 in (b). (c) and (
long  these asymmetric cost curves, the beneﬁt B(vm, vf ) is shown for  = 0 in (c) a
ig. 2.
isease parameters (gender speciﬁc transmission rates and clear-
nce rates) were inferred by ﬁtting the model to US prevalence data
efore and after introduction of the vaccine, and we accounted for
ll Posterior Sets when presenting the simulation results. Focusing
n the two scenarios of pre-existing and new vaccination programs,
ur results suggest that if the costs associated with vaccinating
ales are close to those associated with vaccinating females, then
overage-dependent, increasing marginal costs favor vaccination
trategies that entail immunization of both genders. The potential
mpact of increasing marginal administration costs has been previ-
usly noted (Elbasha and Dasbach, 2010; Bogaards et al., 2011), but
ot formally modeled. To our knowledge, this is the ﬁrst study to
xplicitly address the issue of coverage-dependent marginal costs
n the context of HPV vaccination.
lobal analysis
First, we considered the problem of optimal allocation of ﬁxed
esources in “Global analysis: when a mixed protocol is opti-
al” section, assuming gender symmetric cost curves and uniform
accine distribution. Speciﬁcally, we asked when the optimal
llocation of resources would involve ‘mixed’ strategies, that is vac-
inating positive fractions of both males and females. We  found
hat the nature of the coverage-dependent marginal costs plays a
igniﬁcant role in determining the optimal allocation of resources.
hile the optimal strategy entails female-only vaccination for lin-
ar cost curves (curve A), an increase in convexity in the cost curves
curves B and C) means a shift of the optimal strategy toward equal
istribution of resources among males and females, see Fig. 2.t curve C from Fig. 2a is rendered asymmetric (curves C1 and C2 in insets). Moving
  = 1/2 in (d). For details on averaging and meaning of symbols and error bars, see
Next, we  relaxed the assumption of gender symmetry in the cost
curves in “Impact of asymmetric cost curves” section. Acknowl-
edging that the marginal administration costs may  – e.g. due to a
general lack of awareness of the role of HPV in diseases other than
cervical cancer – be higher for males than females, we  assessed
optimal resource allocation for asymmetric cost curves. We  found
the implications of asymmetry to depend on the convexity of the
cost curves, see Fig. 4. In the case of mildly convex cost curves
(curve B), increasing the degree of asymmetry (curves B1 and B2)
pushes the optimal strategy from ‘mixed’ back to ‘female-only’ vac-
cination. In the case of a more convex cost curve (curve C), the
optimal strategy remains ‘mixed’, even when the male marginal
costs are 25–50% higher than the female marginal costs (curves C1
and C2).
To conclude the discussion of global resource allocation, we
assessed how a possible association between sexual activity and
vaccine uptake would impact the optimal strategy in “Impact of
assortativity in vaccine uptake” section. Here, we found that a neg-
ative correlation between sexual activity and vaccine uptake has
very little impact on the optimal strategy, see Fig. 5a and b. This
is due to the fact that a large fraction of individuals belongs to
the lower sexual activity groups L0 and L1, and hence uniform
uptake across the population is virtually identical to negatively
correlated uptake across the activity levels. In contrast, if vaccine
uptake is positively correlated with sexual activity, see Fig. 5c and
d, then the overall vaccine beneﬁt increases independently of the
cost curve, and increasing convexity (curves B and C) results in dis-
ease eradication across all combinations of male and female vaccine
coverage.
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Fig. 5. Assortative vaccine uptake (symmetric cost curves). The symmetric cost curve analysis of Fig. 2 is repeated with different types of assortative vaccine uptake. (a) and
(b)  Vaccine uptake correlates negatively with sexual activity level: at the beginning of the year, vaccines are distributed among the sexual activity levels as follows: L0 (low
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 = 1/2 (b). (c) and (d
ear,  vaccines are distributed among the sexual activity levels as follows: L3 (high 
0  (low activity) with probability 0. The beneﬁt B(vm, vf ) along the three symmetr
ocal analysis
Next, we assessed optimal allocation of new resources in the
ase of countries with a pre-existing vaccine program, such as the
SA. From the results presented in Fig. 6, it is clear that the optimal
llocation depends critically on the value of the sex-speciﬁc dis-
ase burden  and the nature of the marginal cost curves, and that
ny future recommendation will require an empirical assessment
f these curves. In particular, considering the current coverage in
he USA (vm = 13.9%,  vf = 37%),  the optimal strategy changes from
spend new resources on females” in the case of a linear cost curve
curve A) to “spend new resources on males” in the case of convex
ost curves (curves B and C).
Our results have implications beyond the USA. First, countries
hat have not fully implemented an HPV vaccination program
hould carefully consider the costs and beneﬁts of both-sex vs girls-
nly vaccination. In fact, our results suggest that the highest beneﬁt
rom a vaccine program may  be achieved with a both-sex strat-
gy, provided that the there are considerable coverage-dependent
arginal costs, and provided that these costs are comparable in
agnitude between males and females. Second, a nine-valent vac-
ine is currently in development, with the potential to prevent up to
0% of cervical cancers (Serrano et al., 2012). Particularly in settings
here organized screening is not currently available, the degree
f reduction through vaccination could be comparable, or perhaps
ven better, than screening. Policy makers with limited resources
ight be faced with the choice of introducing a screening program
r a vaccination program, in which case both-sex vaccination may
lay an important role. (high activity) with probability 0. The beneﬁt B (vm, vf ) along the three symmetric
ine uptake correlates positively with sexual activity level: at the beginning of the
y) with probability 1/2, L2 and L1 with probabilities 1/3 and 1/6, respectively, and
 curves A–C (see inset in (c)) is computed for  = 0 (c) and  = 1/2 (d).
Limitations
When interpreting the above results, it is important to be aware
of the various limitations that come with the chosen modeling
approach.
In a trade-off between realism and model simplicity, we
restricted our modeling approach to a closed sexual network of
14–18 years old adolescents, representative of the setting of e.g. a
high school or a small town. This choice reduces the model com-
plexity and the number of parameters considerably, but it comes
with the limitation that relationships outside the network cannot
be accounted for explicitly. Since up to 35–40% of females aged
15–19 have sexual relationships with males who  are 3 or more
years older (Darroch et al., 1999), we performed additional sim-
ulations to assess the sensitivity of our results to the presence of
relationships between females in the network with older males
outside the network, see “The role of external relationships” section
in Appendix E. Since 20–29 years old males have higher prevalence
levels of HPV-16/18 than younger males inside the network, the
external relationships lead to an overall increase in disease bur-
den inside the network. However, we found that adding external
relationships did not change the qualitative nature of the beneﬁt
curves: mixed vaccination strategies remained optimal for sufﬁ-
ciently nonlinear cost curves.
Our choice of four different sexual activity levels (L0–L4),
together with the parametrization of the corresponding partner-
ship initiation and dissolution rates, is likely to have a signiﬁcant
impact on the network topology and the spread of the virus across
the cohort. The average activity distribution of 25% (fraction of
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Fig. 6. Roadmap to herd immunity. The optimal allocation of new resources is analyzed as a function of current coverage levels vm and vf across the 26 Posterior Sets. Plain
black  regions (↑) indicate zones of current coverage levels in which allocating additional resources toward females is most effective for all Posterior Sets; plain white regions
(→)  indicate zones in which allocating resources toward males is most effective for all Posterior Sets; regions where the 26 Posterior Sets exhibit disagreement with respect to
optimal allocation, the color interpolates between black (increase in female coverage is optimal) and white (increase in male coverage is optimal) according to the respective
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ombinations of cost curves (see Fig. 2a for reference) and  values are examined: (a
 and  = 1/2, (e) cost curve B and  = 1/2, (f) cost curve C and  = 1/2
ndividuals in activity level L0), 53% (L1), 20% (L2), and 2% (L3),
uts a rather large weight on the lower end of the sexual activity
pectrum (L0 and L1). Even though the prior ranges used for the sex-
al activity levels are based on epidemiological data, see “Network
arametrization” section in Appendix A for details, it is important
o emphasize that different activity weights (e.g. more individuals
n the higher activity levels) could yield quantitative changes in
ur results. This limitation is particularly relevant for the vaccine
ssortativity analysis of “Impact of assortativity in vaccine uptake”
ection, which depends strongly on the activity distribution.
Another important determinant of the network connectivity is
he degree of concurrency. To calibrate our sexual network model,
e used the degree distribution of a real-life high school net-
ork as reported by Bearman et al. (2004). Even though Bearman
t al. (2004) performed, to our knowledge, the most comprehen-
ive study of an adolescent sexual network to date, their study has
everal limitations, which in turn may  have inﬂuenced the results
resented in the current study. More precisely, the students in the
earman network may  not have been representative of students
rom similar schools, and the number of reported relationships
as truncated, which may  have introduced considerable bias in
he inferred degree distribution (Boily et al., 2013).
In our model, sexual mixing is explicitly assortative by gender,
ge and sexual activity level. However, there are a number of addi-
ional factors such as socioeconomic status and race/ethnicity that
ave been shown to determine sexual mixing patterns (Santelli
t al., 2000). Since these attributes are not accounted for the in
he current model, we cannot comment on their potential impact
n the predicted beneﬁts under increased male vaccination.l corresponds to herd immunity conferring coverage levels (R∗ < 1). The following
 curve A and  = 0, (c) cost curve B and  = 0, (c) cost curve C and  = 0, (d) cost curve
Since we focused on prevalence of genital HPV-16/18 infections
in the population of 14–18 years old adolescents, our framework
is not amenable to a complete cost-effectiveness analysis. Costs
incurred by infections with low-risk HPV types causing genital
warts, as well as oral and anal HPV infections would also need to be
included. Additionally, the incidence of most HPV-related cancers
is much smaller in individuals aged 14–18 years than in sub-
populations of older individuals, and an age-structured modeling
approach would be required to assess the costs due to HPV-related
cancers. Nevertheless, sufﬁcient prevalence levels in adolescent
populations are critical for the survival of HPV in the entire popula-
tion, and incidence levels peak – particularly in females – at a young
age (Winer et al., 2003; Partridge et al., 2007). Therefore, reduction
of the virus among adolescents is the crucial ﬁrst step toward herd
immunity.
Finally, our models only describe heterosexual relationships,
and it is a priori not clear how the inclusion of bi- and homosexual
individuals would affect our conclusions. Importantly, sexual ori-
entation is usually not deﬁned by the age of vaccine administration,
which makes it impossible to target groups by sexual orientation.
This issue will be addressed in future work.
In summary, our analysis shows that coverage-dependent
marginal costs may, depending on their true magnitude, play a crit-
ical role in optimizing the distribution of resources among female
and male vaccination programs, both in the USA and elsewhere. In
light of our ﬁndings, the conclusions of previous cost-beneﬁt analy-
ses of male vaccination that employed linear cost curves may  need
to be re-evaluated carefully. Most importantly, since there is cur-
rently a lack of empirical data on the marginal administration costs
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f HPV vaccination, more research is needed to quantify the true
ost curves and make speciﬁc policy recommendations.
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ppendix A. Agent-based model
odel structure and dynamics
Network structure. The model consists of a closed cohort of
exually active adolescents, containing N females and N males. Indi-
iduals enter the cohort at age 14 and leave when they turn 19 years
ld. Aging of the population is modeled deterministically, and an
qual number of individuals are in each age group. The 2N indi-
iduals (graph nodes) can engage in sexual relationships (graph
dges), break up existing relationships, and transmit HPV-16/18
long active network edges. Each node in the network has three
haracteristics: gender g ∈ {m, f}, age a ∈ {1, 2, . . .,  5} (where a = 1
tands for age group 14, etc.) and sexual activity level l ∈ {0, 1, 2, 3}
where l = 0 corresponds to the lowest activity level L0, etc.).
Network dynamics. Similarly to previous studies (Van de Velde
t al., 2010; Malagón et al., 2013), we adopt a female-centric per-
pective to deﬁne the network dynamics. Each female initiates
ew relationships at rate e1(a, l), depending on both her age (a)
nd activity level (l). Once a female node decides to initiate an
dge, a male node is chosen according to the assortative mixing
atrix M(a, l ; a′, l′), whose elements describe the probability that
 female of type (a,l) chooses a male of type (a’,l’). We  allow for
oncurrent relationships, but enforce a penalty for increasing per-
ode concurrency as follows: if a female node chooses a male node
according to the mixing matrix M),  the node is accepted with prob-
bility (#f  + 1)−1(#m + 1)−1, where #f and #m are the number of
lready active relationships of the female and male node, respec-
ively. Like this, the acceptance probability is 1 for two  single nodes,
nd decreases with an increasing number of already existing rela-
ionships. If a relationship is rejected, we repeat the process and
ick a new male in agreement with the assortativity matrix M,  until
 partner is accepted. One key advantage of this simple rejection
ule is its independence from additional parameters. Furthermore,
ithout this rule, we were unable to ﬁt the cumulative degree dis-
ribution of a real-life sexual network, see “Network calibration”
ection in Appendix A. Finally, edges are dissolved by the female
ode at rate e0(a, l).Disease dynamics. Each node is either susceptible (S), infected
I) or recovered (R). Incoming nodes are either susceptible or vac-
inated, in which case they fall into the category of recovered
odes (assuming a 100% vaccine efﬁcacy throughout the study).cs 11 (2015) 32–47 41
Transmission of the virus can take place along active edges between
infected and susceptible nodes. The transmission rates are gender
speciﬁc: ˇmf between infected male and susceptible female, and ˇfm
between infected female and susceptible male. Infected individuals
clear the virus at rates f, m. Upon clearing the virus, previously
infected nodes either develops immunity with probability pf, pm
and becomes recovered, or go back to the pool of susceptible nodes
otherwise.
Simulations
The model was  simulated for N = 1500 in discrete time, with a
time stepping interval of t  = 0.025 years (≈10 days). All simula-
tions were performed with the software MATLAB (© 1984–2014,
The Mathworks, Inc). At each time step, the network parameters
were re-sampled (see below for details), and we  proceeded in 5
steps.
1. Edge dissolution: each female engaged in at least one relation-
ship dissolves one of her relationships with probability t  e0(a,
l).
2. Edge formation: each female activates an edge with probability
t  e1(a, l), and chooses a male partner according to the mixing
matrix M and the rejection rule for concurrent relationships (see
above).
3. Recovery of infected nodes: each infected individual clears its
infection with probability t  f or t  m, and either becomes
recovered (probability pf or pm) or susceptible otherwise.
4. Disease transmission: along active edges between susceptible
and infected individuals the virus is transmitted with probability
t ˇmf if the male is infected, and with probability t  ˇfm if the
female is infected.
5. Once a year, the individuals in age group a = 5 leave the cohort,
and the remaining age groups move up to the next age level. The
now empty age group a = 1 is ﬁlled with the incoming group of
susceptible and recovered (if vaccinated) individuals.
Network parametrization
To parametrize the network dynamics, we  relied in part on prior
estimates from the work of Van de Velde et al. (2010). Since their
network model is slightly different to ours (they do not allow for
concurrent relationships), we made the following adjustments.
• In Van de Velde et al. (2010), only single women can initiate a
relationship. Therefore, our edge formation rate e1(a, l) is related
to Van de Velde et al.’s (2010) female relationship initiation rate
(f, a, l) according to
Ntotal(f, a, l)e1(a, l) = Nsingle(f, a, l)(f, a, l),
where Ntotal(f, a, l) and Nsingle(f, a, l) are the total number of females
and the number of single females in compartment (a, l) at station-
arity, respectively. Noticing that in Van de Velde et al. (2010) the
expected number of singles in compartment (a, l) is
ENsingle(a, l) = Ntotal(a, l)
ˆ(a, l)
ˆ(a, l) + (f, a, l) ,
where ˆ(a, l) is Van de Velde et al.’s (2010) edge dissolution rate
(we denote their  by ˆ to avoid confusion with our clearance
rate ), we ﬁnd that
e1(a, l) ≈ s(a, l)(f, a, l), (4)
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Table 2
Age mixing matrix (a, a′). Each entry speciﬁes the probability of a female in age
group a to choose a male partner in age group a′ . Values derived from Table 2 in
Kaestle et al. (2002) after excluding partnerships outside the model age range 14–18
years.
a a′ 1 2 3 4 5
1 0.277 0.198 0.197 0.197 0.131
2  0 0.318 0.228 0.227 0.227
3  0 0 0.54 0.23 0.23
4  0 0 0 0.705 0.295
5  0 0 0 0 1
Table 3
Relationship initiation rates (g, a, l): prior ranges. Lower L and upper U bounds of
prior ranges for (f, a, l) and (m, a, l) as reported in Van de Velde et al. (2010). Units
for rates: per year.
L(f, l) U(f, l) L(m,  l) U(m, l)
l = 0 0.44 1.05 0.53 1.73
l  = 1 0.74 1.78 0.9 2.94
l  = 2 2.04 4.31 2.47 7.12
l  = 3 4.29 8.74 5.21 14.41
Table 4
Relationship dissolution rates (f, a, l): prior ranges. Lower L and upper U bounds
of  prior ranges for (f, a, l) as reported in Van de Velde et al. (2010). Units for rates:
per year.
ˆL(f, l) ˆU (f, l)
l = 0 0.1 0.74
l = 1 0.12 0.88
l  = 2 0.14 1.04
l  = 3 0.32 2.4
Table 5
Fraction of individuals in different sexual activity groups: prior ranges. Lower 	L
and upper 	U bounds of prior ranges for the estimated fraction of individuals in
each sexual activity group as reported in Van de Velde et al. (2010).
	L(l) 	U(l)
l = 0 0.16 0.36
l  = 1 0.41 0.67
l  = 2 0.14 0.272 M.D. Ryser et al. / Ep
where
s(a, l) = ˆ(a, l)
ˆ(a, l) + (f, a, l) .
Because our model does, in contrast to Van de Velde’s model,
allow for concurrency, and because (4) is only an approximation,
we introduced an ad hoc scaling factor E and replaced (4) by
e1(a, l) ≈ E s(a, l)(f, a, l), (5)
Importantly, E is the only free parameter in the network dynam-
ics, see below for details on the inference of E.
Our relationship dissolution rate e0(a, l) corresponds directly to
Van de Velde et al.’s (2010) dissolution rate ˆ(a, l).
To characterize the mixing matrix M,  we deﬁned
M(a, l; a′, l′) = (l, l′|a′)(a, a′),
where (a, a′) is the age mixing matrix between females of age a
and males of age a′, and (l, l′|a′) is the activity level mixing matrix
between females of activity l and males of activity l′, conditioned
on having chosen the age group a′ for the potential male partner.
To parametrize the age mixing matrix (a, a′), we  used empirical
data on age assortativity in sexual relationships from (Kaestle
et al., 2002). Since our model cohort is closed, we discarded
relationships that are connected to the outside of the 14–18
year bracket, and renormalized the in-cohort mixing probabilities
reported in Table 2 of Kaestle et al. (2002).
For the sexual activity mixing matrix (l, l′|a′) we followed
the rationale in Van de Velde et al. (2010). After correction of
their expression for  (see (Walker et al., 2012) for details), we
obtained
(l, l′|a′) = W(l,  l
′)N(m, a′, l′)(m, a′, l′)∑
l′W(l, l
′)N(m, a′, l′)(m, a′, l′)
,
where N(m, a′, l′) is the number of males in group (a′, l′), (m, a′,
l′) is the partnership formation rate of males in group (a′, l′), and
W(l, l′) is the preference matrix, deﬁned in terms of the assortative
degree parameter  as
W(l, l′) =
{
 if l = l′
1, if l /= l′.
(6)
Regarding the numerical parameter values (see Table 1 for an
verview), we performed a dynamic re-sampling scheme for most
etwork parameters to account for parameter uncertainty.
We classiﬁed the networks parameters into the following
roups:
Group 1. The age mixing matrix (a, a′) and the scaling factor E
were kept constant throughout all simulations. (a, a′) is given
in Table 2 and E was obtained by inference, see Table 1.
Group 2. The parameters (g, a, l), ˆ(a, l) and , which together
specify the edge rates e0 and e1 as well as the activity matrix (l,
l′|a′), were re-sampled dynamically after each time step, using
prior ranges obtained from the literature, see Tables 3 and 4 for
the ranges of  and ˆ, respectively, and Table 1 for the prior range
of . For  and , we sampled from uniform distributions between
the lower and upper bounds of the reported prior ranges. The
sampling for  was more involved. In fact, since sexual activity
generally increases between ages 14 and 18, we assumed (g, a,
l) to be a linearly increasing function of age. More precisely, for
each update we drew two random numbers r1 and r2 uniformly
on [0, 1] and [r1, 1], respectively, and then determined (g, a, l)l = 3 0.01 0.02
in terms of the lower L(g, a, l) and upper bounds U(g, l) of the
prior range as follows:
(g, a, l) = L(g, l) + r1[U(g, l) − L(g, l)]
+ a − 1
4
(r2 − r1)[U(g, l) − L(g, l)].
• Group 3. The distribution of incoming individuals across the sex-
ual activity levels was  done probabilistically, and the respective
fractions in each level, 	(l), were drawn uniformly from their prior
range (see Table 5) and then normalized to sum to unity. The prior
ranges in Table 5 were derived in the Supporting Information of
Van de Velde et al. (2010) based on data from the Canadian PISCES
study (Drolet et al., 2012). In short, the four groups L0-L3 corre-
spond to 0–2, 2–10, 11–39 and 40+ lifetime sex partners, and
normal and abnormal Pap cohorts in the PISCES study were used
to derive upper and lower bounds for the fraction of females in
the respective activity groups. The male prior ranges for the dif-
ferent activity levels coincide with the female prior ranges, but
males have higher partnership initiation rates than females in the
same activity group, see Table 3.
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Table  6
Empirical degree distribution of adolescent sexual network. From Fig. 2 in Bearman et al. (2004) we determined the degree distribution (total population) of the cumulative
sexual network graph over a period of 18 months in Jefferson high school.
Degree 0 1 2 3 4 5 6 7+
Fraction 0.3113 0.4014 0.1611 0.0601 0.0433 0.0096 0.0024 0
0 2 4 6 8 10
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Fig. 7. Degree distribution of sexual network. For E = 1.5, the network is ﬁrst run
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Table 7
Prevalence intervals for model calibration. All values in %. For female prevalence of
HPV-16/18 before (2006) and after (2010) introduction of the vaccine we used 95%
conﬁdence intervals from (Markowitz et al., 2013). In absence of reliable pre-vaccine
prevalence estimates for males, we followed (Satterwhite et al., 2013; Dunne et al.,
2006) and used the same conﬁdence intervals as for females. Vaccine uptake levels
(vm , vf ) as reported by the CDC (Centers for Disease Control and Prevention, 2014).
Year If/N vf Im/N vmntil stationarity, and then the degree distribution of the cumulative network graph
ver 18 months (50 simulations, solid lines) is compared to the empirical degree
istribution (star) as reported in Bearman et al. (2004).
etwork calibration
The only free parameter in the above network model is the scal-
ng factor E appearing in the deﬁnition of e1 in (5). To estimate the
alue of E, we used the cumulative graph of a real-life high school
exual network (Bearman et al., 2004). From Fig. 2 in Bearman
t al. (2004), we extracted the degree distribution of the cumulative
raph over 18 months, see Table 6. Running our network model to
teady-state and then computing the cumulative graph over an 18
onths period, we compared the obtained degree distribution to
he real-life distribution from (Bearman et al., 2004), and estimated
 = 1.5, using a least square-ﬁt starting from a prior range E ∈ [1,  2].
he optimal ﬁt is shown in Fig. 7.
isease dynamics parametrization
The disease-related parameters are the transmission rates ˇmf
nd ˇfm, the clearance rates m/f and the probabilities pm/f of
eveloping immunity against re-infection with HPV-16/18 after
learing the virus. Following the group deﬁnitions introduced for
he network parameters in “Network parametrization” section
n Appendix A, the probabilities pm/f were placed into Group 3
updated for each incoming cohort), and were assumed to be
erson-speciﬁc, that is they were sampled uniformly at random
rom the ranges in Table 1 for each incoming individual. The
emaining disease parameters ˇmf, ˇfm and m/f were used to ﬁt the
odel-derived prevalence levels to empirically measured preva-
ence data of infections with HPV-16/18 among adolescents. Based
n evidence about gender-speciﬁc differences in transmission
ates(Hernandez et al., 2008; Widdice et al., 2013), we  introduced
wo independent rates ˇfm and ˇmf. Regarding the virus clear-
nce, data suggests similar rates for males and females (Giuliano
t al., 2011; Moscicki et al., 2004), and hence we used a single
ate  = m = f. Of note, gender-related differences in the immune
esponse are captured in the probabilities pm/f.2006 [5.8, 8.7] 0 [5.8, 8.7] 0
2010  [2.5, 5] 32 - 0
Data about the vaccine impact on prevalence levels is still
scarce, and, to our knowledge, good estimates are only available
for females, see (Markowitz et al., 2013). The prevalence levels
reported in (Markowitz et al., 2013) together with the correspond-
ing vaccine uptake levels from the CDC (Centers for Disease Control
and Prevention, 2014) are summarized in Table 7. Even though
(Markowitz et al., 2013) only reports on female prevalence lev-
els, we are not aware of any evidence that there is a signiﬁcant
difference between pre-vaccine male and female prevalence lev-
els, see also (Satterwhite et al., 2013). In particular, using the same
calibration intervals for males and females is compatible with the
very broad pre-vaccine estimates of 1.3–72.9% (males) and 14%-
90% (females) in Dunne et al. (2006). To infer posterior values for
the transmission and clearance rates, we sampled 1000 parame-
ter triples (ˇfm, ˇmf, ) uniformly across prior ranges (see Table 1),
ran 50 realizations of the process for each parameter triple over 30
years, time-averaged each realization between years 15 and 30, and
ﬁnally averaged the 50 time-averages to obtain a representative
prevalence level for each parameter triple. We  only retained param-
eter sets that met  the following criteria of a good ﬁt. 1) Both male
(Im/N) and female (If/N) pre-vaccine prevalence levels (year 2006)
were within the 95% conﬁdence interval reported in Markowitz
et al. (2013). 2) Post-vaccine female prevalence levels (year 2010)
were within the 95% conﬁdence interval reported in Markowitz
et al. (2013). According to this procedure, we retained a Posterior
Set of 26 parameters triples (ˇfm, ˇmf, ) among the 1000 tested
sets, see Table 8.
Appendix B. Deterministic compartment model
Model description
To derive the deterministic CM,  we  neglect the heterogeneous
network structure, i.e. we consider the continuous-time jump
Markov process (Sm, Sf , Im, If , Rm, Rf )t on the complete bipartite
graph. The transition rates for the male population then given by⎧⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪
Sm → Sm + 1 @ rate (1 − vm)N,
Sm → Sm − 1 @ rate Sm +
ˇfm
N
SmIf
Im → Im + 1 @ rate
ˇfm
N
SmIf
Im → Im − 1 @ rate ( + m)Im
(7)⎪⎪⎪⎪⎪⎪⎪⎩ Rm → Rm + 1 @ rate mIm
Rm → Rm − 1 @ rate Rm.
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Table 8
Posterior set. The 26 posterior parameter sets retained after calibration of the model
to  prevalence data, see text for details. Units for rates: per year.
Set # ˇfm ˇmf 
1 42.8 145.8 0.63
2  42.8 166.4 0.63
3  42.8 187.0 0.63
4  63.4 187.0 0.77
5  84.0 63.4 0.63
6  84.0 125.2 0.77
7  84.0 145.8 0.77
8 84.0 166.4 0.77
9  84.0 187.0 0.77
10  104.6 63.4 0.63
11  104.6 104.6 0.77
12  104.6 125.2 0.77
13  104.6 145.8 0.77
14 125.2 63.4 0.63
15  125.2 104.6 0.77
16  125.2 125.2 0.77
17  145.8 104.6 0.77
18 145.8 125.2 0.77
19  145.8 187.0 0.91
20  166.4 84.0 0.77
21  166.4 104.6 0.77
22  166.4 187.0 0.91
23 187.0 84.0 0.77
24  187.0 104.6 0.77
i
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s
f
S
c
y
p
s
i
p

o25  187.0 166.4 0.91
26  187.0 187.0 0.91
The rates for the female population can easily be obtained by
nterchanging the m and f indices in (7). Next, we pass to the large
opulation limit to average out the stochastic ﬂuctuations in the
ystem. To this end, it is convenient to introduce the sub-population
ractions for all state variables as X˜(t) := X(t)N , where X  {Im, If, Sm,
f, Rm, Rf} . Using standard results from the theory of Markov pro-
esses, see e.g. (Kurtz, 1970), the large population limit (N →∞)
ields the following system of mean ﬁeld equations for the male
opulation fractions,
d
dt
∼
Sm = −ˇfm
∼
Sm
∼
I f + (1 − vm) − 
∼
Sm
d
dt
∼
I m = ˇfm
∼
Sm
∼
I f − ( + m)
∼
I m
d
dt
∼
Rm = m
∼
I m − 
∼
Rm.
(8)
The mean ﬁeld equations for the female population are obtained
imilarly by simply interchanging the indices m and f. Rescal-
ng time as t = −1 t˜ results in the following set of dimensionless
arameters: ˜ˇmf = ˇmf / , ˜ˇ fm = ˇfm/ ,  ˜m = m/ ,  ˜f = f / ,  and
˜  = 1. Introducing the rescaled time in (8) and omitting tildes, we
btain
d
dt
Sm = −ˇfmSmIf + (1 − vm) − Sm
d
dt
Sf = −ˇmf SfIm + (1 − vf ) − Sf
d
dt
Im = ˇfmSmIf − (1 + m)Im
d
dt
If = ˇmf SfIm − (1 + f )If
d
(9)dt
Rm = mIm − Rm,
d
dt
Rf = f If − Rf .cs 11 (2015) 32–47
Naturally, we  only study solutions of (9) such that (Sm, Sf, Im, If,
Rm, Rf)  [0, 1] 6 as well as
Sm + Im + Rm + vm = 1 and Sf + If + Rf + vf = 1.
It is important to emphasize that the mean ﬁeld equations (9)
are not merely the large population limit of the full stochastic ABM
introduced above. Indeed, we ﬁrst discarded the network hetero-
geneity before taking the limit N →∞. Nevertheless, we  expect the
original ABM to exhibit similar qualitative features as the jump-
process (7) and the compartment model (9). This resemblance is
illustrated by direct comparison of the qualitative features dis-
played in Figs. 2 and 3.
The long-term dynamical behavior of the system (1) has been
well-characterized. For certain parameter regimes, there is a
disease-free equilibrium with (Im, If) = (0, 0), and it is stable if
and only if the basic reproduction number R∗ for the CM satis-
ﬁes R∗ ≤ 1. In the current context, R∗ is deﬁned as the expected
number of same-sex secondary infections of an infected individ-
ual. In fact, the potentially asymmetric transmission ˇfm and ˇmf
require that this number be deﬁned atypically, and we deﬁne it as
the expected number of secondary infections in the same sex, when
a single infected individual is introduced to a susceptible popula-
tion. The reason for this modiﬁed deﬁnition is so that R∗ > 1 is
the condition for the existence of an endemic, and the sex of the
initially infected individual does not matter. It is possible for the
expected number of males infected by a single initially infected
female to be less than 1, and still have an endemic state (R∗ > 0)
in our model. In the case where our model is symmetric (parame-
ters for males and females are identical), our deﬁnition of R∗ is the
square of the traditional reproduction number R0. According to the
above deﬁnition,
R∗ =
ˇfmˇmf (1 − vm)(1 − vf )
(1 + m)(1 + f )
.  (10)
If R∗ ≤ 1, then the disease-free equilibrium is globally asymp-
totically stable (Elbasha, 2008), a situation known as herd immunity.
On the other hand, if R∗ > 1, then the disease-free equilibrium is
unstable, and there is exactly one endemic equilibrium point, given
by (recall that all rates were rescaled by )
Im(vm, vf ) =
ˇ(1 − vf )(1 − vm) − s
ˇmf s + ˇ(1 + m)(1 − vf )
,
If (vm, vf ) =
ˇ(1 − vf )(1 − vm) − s
ˇfms + ˇ(1 + f )(1 − vm)
,  (11)
where  ˇ = ˇmf ˇfm, s ≡ (1 + f )(1 + m). Furthermore, if R∗ > 1,
then this endemic equilibrium is globally asymptotically stable,
which means that the endemic equilibrium exists and is globally
asymptotically stable if and only if R∗ > 1 (Elbasha, 2008).
Model parametrization
The CM dynamics are characterized by 4 parameters only: 1/ ,
which is the average time spent in the cohort, the gender-speciﬁc
transmission rates ˇmf and ˇfm, as well as the clearance rate .
While 1/  is ﬁxed to 5 years for our purposes, we used the 26 Pos-
terior Sets from the ABM for the remaining parameters. In addition,
the two transmission rates ˇfm and ˇmf were rescaled by a network
connectivity parameter ı to account for the fact that the network
structures in the ABM and the CM are inherently different. In other
words, we  replaced ˇmf and ˇfm by ıˇmf and ıˇfm, respectively. To
obtain the best estimate of ı we  proceeded analogously to the ﬁt-
ting procedure for the transmission and clearance rates in “Disease
dynamics parametrization” section: for each of the 26 Posterior Sets
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Table  9
Risk of progression. The following estimates are used to calculate the above probabilities. (1) Fractions of cancers associated with HPV infection as reported in Jemal et al.
(2013): 100% for cervical cancer, and 40% each for vulvar, vaginal and penile cancers. (2) Lifetime incidence risk of the different cancers from Table 2 in Chesson et al. (2011).
(3)  An estimated 79% lifetime risk of HPV infection according to the study by Syrjanen et al. (1990).
CIN 1 CIN 2 CIN 3 Cervix Vulva Vagina Penis
pf 5.8 · 10−3 3.6 · 10−3 1.5 · 10−3 1.6 · 10−4 2.4 · 10−5 7.6 · 10−6 -
pm – – – – – – 1.4 · 10−5
Table 10
Estimated costs per cancer case. Data from Table 2 in Chesson et al. (2011), in USD.
See their manuscript for more information.
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Fig. 8. Ratio of marginal administration to marginal ﬁxed costs. For the cost function
level sets in Fig. 2a, the ratio of marginal costs of vaccine administration to marginal
ﬁxed costs (vaccine price) is shown for increasing single sex coverage v. For curveCIN 1 CIN 2 CIN 3 Cervix Vulva Vagina Penis
Cost 1,959 3,642 4,135 33,894 35,693 19,697 18,528
e estimated ı by ﬁtting the model-derived pre- and post-vaccine
revalence levels to the empirical data in Table 7.
ppendix C. Estimation of 
By deﬁnition,  is the average cost of a male genital infection
elative to the cost of a female genital infection. To determine the
verage cost of an infection, we have to compute the probability
hat an infected individual will eventually develop precancer or
ancer, and assess the costs incurred by the different types of HPV-
ssociated diseases. More precisely, the average costs Cf and Cm for
emales and males are given by
f =
Nf∑
i
pf,icf,i, Cm =
Nm∑
i
pm,icm,i, (12)
here pf,i and pm,i are the gender-speciﬁc probabilities of progres-
ion from infection to disease of type i, cf,i is the gender-speciﬁc
ost associated with diagnosis of disease type i, and Nf and Nm are
he total numbers of diseases associated to infection with HPV-
6/18. Once Cm and Cf have been estimated, the relative cost of
ale infections is given by
 = Cm
Cm + Cf
. (13)
It remains to estimate the parameters in (12).
Diseases to be included for females are cervical intraepithelial
neoplasia (CIN) 1, CIN 2, CIN 3, cervical cancer, vaginal cancer
and vulvar cancer (Nf = 6). For males, we include penile cancer
only (Nm = 1). Since we do not model anal or oral HPV infections
or infections with low-risk types, we exclude anal and oropharyn-
geal cancers as well as genital warts for the estimate of .
To estimate the probability of progression, we ﬁrst determine the
fraction of cases associated with HPV for each cancer type. Then
we calculate the risk of progression by combining the lifetime risk
of HPV infection with the overall population incidence levels of
the different cancers. For details see Table 9 and caption. Of note,
CIN 1, 2 and 3, and cervical cancer are sequential disease stages,
and we assume here that incident cases in either stage had gone
unnoticed through the previous stages.
To estimate the disease-related costs, we use again the data from
Chesson et al. (2011), see Table 10.Using the tabulated values (Tables 9 and 10) and Eqs. (12) and
13), we ﬁnd estimates of Cm = 0.26, Cf = 37.16 and estimated
alue of
 = 7 · 10−3.A  there are no marginal administration costs, and the mildly convex cost curve has
steeper marginal administration costs (relative to marginal ﬁxed costs) than the
more convex curve C.
Finally, we  emphasize that our analysis does not include potential
costs incurred by oral and anal HPV infections as well as infections
with low-risk strains of HPV. Since this would require considering
oral-anogenital HPV transmissions as well as explicit modeling of
low-risk vaccine strains (HPV-6/11), our current framework is not
suitable for a complete analysis.
Appendix D. Marginal costs: administration vs. ﬁxed
To provide a better understanding of the different cost function
level sets in Fig. 2a, the ratio of marginal costs of vaccine adminis-
tration to marginal ﬁxed costs (vaccine price) is shown for curves
A–C in Fig. 8.
Appendix E. The role of external relationships
The model developed in this manuscript consists of a closed
dynamic network of 14–18 years old adolescents. In particular, it
does not account for potential relationships with older sex part-
ners outside the network. Since an estimated 37% of adolescent
females have relationships with males who are 3 or more years
older (Darroch et al., 1999), we  assess here the impact of external
relationships on the model results. To this end, and according to the
above estimate, we introduce an internal partnership initiation rate
eint1 (a, l) = 0.63 · e1(a, l), where e1(a, l) is the partnership initiation
rate used in all other simulations, and an external partnership initi-
ation rate eext1 (a, l) = 0.37 · e1(a, l). The network internal dynamics
remain unchanged except for the replacement of e1 by eint1 , whereas
the external relationships are modeled as follows:
• Each female who is currently not in an external relationship initi-
ates a relationship with a male aged 20–29 years at rate eext1 (a, l).• The external male entering the sexual relationship with the
internal female is assumed to be infected with HPV-16/18 with
probability pext.
• The relationship with the external edge is dissolved at the usual
rate e0(a, l). During an ongoing relationship with an infected
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aig. 9. Impact of external relationships. The simulation of Fig. 2 is repeated for a sce
f  HPV-16/18 among external males was set to pext = 0.12 · vm , and in (c) and (d) it 
external male, a susceptible internal female can get infected
according to the male-to-female transmission rate ˇmf.
The only additional parameter in these dynamics is pext, the
ikelihood of an external male being infected with HPV-16/18. To
ssess the most extreme scenario – corresponding to a maximal
njection of virus from outside the network – we  assumed that
he prevalence of HPV-16/18 in external males corresponds to the
eak-prevalence in absence of any vaccine, only reduced by the
ale vaccine uptake vm. In particular, we ignored further reduc-
ions due to herd immunity effects because these can only be
stimated by explicitly extending the model to account for older
ndividuals. Due to a lack of data, the peak prevalence of HPV-16/18
mong men  aged 20–29 years needed to be estimated indirectly.
hereby, we assumed that the ratio of peak HPV-16/18 prevalence
etween males and females before the introduction of the vaccine
s equal to the ratio of peak incidence of genital warts between
ales and females. The estimated pre-vaccine peak prevalence
f HPV-16/18 in females aged 20–29 years was estimated at 15%
Markowitz et al., 2013). Next, based on Fig. 2 in Patel et al. (2013),
e estimated the ratio of male to female peak incidence rates of
enital warts to be approximately 0.79. Combining these estimates,
e found an estimated peak prevalence of HPV-16/18 in males aged
0–29 years of 12%, and the respective estimate for the HPV-16/18
revalence of external males in our simulations is pext = 0.12 · vm.
he corresponding simulation results for the most extreme sce-
ario (pext) as well as an intermediate scenario (0.5 · pext) are shown
n Fig. 9. As expected, the relationships of internal females with
xternal males (whose HPV-16/18 prevalence is higher than the
ne of internal males) leads to an overall decrease of the vaccine
eneﬁt, see Fig. 2 for comparison. For both values of HPV prevalence
mong external males, the female-only beneﬁt ( = 0) is roughlyith both network internal and external relationships. In (a) and (b), the prevalence
t to 0.5 · pext .
one percentage-point lower than the population beneﬁt ( = 1/2),
compare Figs. 9a and c with b and d, respectively. This is due to the
fact that accounting for relationships with external males increases
primarily the prevalence of HPV among internal females, but not
males. Finally, and most importantly, we  remark that the qualita-
tive observation from Fig. 2 remains unaltered when accounting
for relationships with older males: the vaccine beneﬁt is highest
for mixed vaccination regimes for the convex cost curves B and C.
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